GenomeSmart

GenomeSmart was a private U.S. digital health and genomics software company that developed AI- and machine learning-based genetic risk assessment and test recommendation tools for use in healthcare. Its flagship product, GenomeBrain, was designed to help patients, clinicians, health systems, laboratories, and payers identify appropriate genetic tests based on personal and family history, ethnicity, age, clinical guidelines, and insurance considerations. The company initially launched with support for hereditary cancer and reproductive genetic testing and indicated plans to expand into cardiovascular genetics and pharmacogenomics. GenomeSmart appears to have been acquired in 2020 by Konica Minolta Precision Medicine, and company-profile sources now describe it as closed or acqui-hired rather than operating independently. Overall, it fit best as a healthcare IT/genomics platform company rather than a therapeutics developer.